リノボRx
RenovoRx, Inc.
RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q2 | -0.06 | $909,000 | -$3M |
| 2026 Q1 | -0.09 | $563,000 | -$4M |
| 2025 Q4 | -0.08 | $238,000 | -$3M |
| 2025 Q3 | -0.08 | $266,000 | -$2M |
| 2025 Q2 | -0.08 | $422,000 | -$2M |
| 2025 Q1 | -0.08 | $197,000 | -$3M |
| 2024 Q4 |
| -0.13 |
| $43,000 |
| -$2M |
| 2024 Q3 | -0.10 | $0 | -$2M |